Iovance Biotherapeutics (IOVA) Share-based Compensation (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Share-based Compensation of $8.7 million for Q1 2026, down 62.03% year-over-year from $22.9 million in Q1 2025, and up 117.7% quarter-over-quarter from -$49.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Share-based Compensation (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Share-based Compensation for 15 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 62.03% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (down 94.27% YoY), while the FY2025 annual figure was $43.8 million, down 60.05% from the prior year.
- Share-based Compensation climbed to $8.7 million in Q1 2026 per IOVA's latest filing, from -$49.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $97.6 million in Q4 2024 and bottomed at -$61.9 million in Q4 2022.
- Historically, Share-based Compensation has averaged $7.9 million across 5 years, with a median of $4.7 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 218.63% — and 2024, when it surged 10235.33%.
- Iovance Biotherapeutics' Share-based Compensation stood at -$61.9 million in 2022, then surged by 123.28% to $14.4 million in 2023, then surged by 578.17% to $97.6 million in 2024, then slumped by 150.34% to -$49.2 million in 2025, then jumped by 117.7% to $8.7 million in 2026.
- Business Quant data shows IOVA's Share-based Compensation at $8.7 million in Q1 2026, -$49.2 million in Q4 2025, and $11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 11.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.73 Mn |
| Jun 30, 2026 | 11.73 Mn |
| Mar 31, 2026 | 8.70 Mn |
| Mar 31, 2026 | 8.70 Mn |
| Dec 31, 2025 | -49.16 Mn |
| Dec 31, 2025 | -49.16 Mn |
| Sep 30, 2025 | 11.90 Mn |
| Sep 30, 2025 | 11.90 Mn |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 22.92 Mn |
| Mar 31, 2025 | 22.92 Mn |
| Dec 31, 2024 | 97.65 Mn |
| Dec 31, 2024 | 97.65 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 4.70 Mn |
| Mar 31, 2024 | 4.70 Mn |